0QCO Stock Overview
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Pharming Group N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.89 |
52 Week High | €1.31 |
52 Week Low | €0.86 |
Beta | 0.73 |
1 Month Change | -11.57% |
3 Month Change | -23.17% |
1 Year Change | -12.26% |
3 Year Change | -15.89% |
5 Year Change | 8.73% |
Change since IPO | -91.10% |
Recent News & Updates
Recent updates
Shareholder Returns
0QCO | GB Biotechs | GB Market | |
---|---|---|---|
7D | 1.0% | -0.4% | 2.2% |
1Y | -12.3% | -29.1% | 0.9% |
Price Volatility
0QCO volatility | |
---|---|
0QCO Average Weekly Movement | 4.9% |
Biotechs Industry Average Movement | 6.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0QCO's share price has been volatile over the past 3 months.
Volatility Over Time: 0QCO's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1988 | 382 | Simon de Vries | www.pharming.com |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Pharming Group N.V. Fundamentals Summary
0QCO fundamental statistics | |
---|---|
Market cap | €593.30m |
Earnings (TTM) | -€9.83m |
Revenue (TTM) | €228.59m |
2.6x
P/S Ratio-60.4x
P/E RatioIs 0QCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0QCO income statement (TTM) | |
---|---|
Revenue | US$245.32m |
Cost of Revenue | US$25.21m |
Gross Profit | US$220.10m |
Other Expenses | US$230.65m |
Earnings | -US$10.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
Earnings per share (EPS) | -0.016 |
Gross Margin | 89.72% |
Net Profit Margin | -4.30% |
Debt/Equity Ratio | 63.3% |
How did 0QCO perform over the long term?
See historical performance and comparison